Blanching of the Nasal Ala Minutes After Filler Injection
A 38-year-old woman has 0.4 mL of cross-linked hyaluronic acid injected with a 30-gauge needle into the left nasal ala for a "liquid rhinoplasty." Within seconds she reports sharp pain, and the injector sees a 1 cm area of blanching with a reticulated violaceous border extending onto the left nasal sidewall; capillary refill is 4 seconds. The clinic has hyaluronidase 1500 IU/mL vials, nitroglycerin paste, warm compresses, and aspirin on hand. She is healthy, has no allergy history, and had 1 mL of the same product in the same area eight months ago without incident. It is 6:10 p.m.; the clinic closes at 7 p.m. and the nearest emergency department is 20 minutes away.
1. Give your immediate step-by-step management, including hyaluronidase dosing and rationale.
Read the worked answer
Recognise and act - this is vascular occlusion of the angular/nasal arterial territory, not bruising.
- Stop injecting immediately. Do not inject more product and do not spend time on massage debate.
- Reconstitute hyaluronidase and infiltrate now. Using 1500 IU/mL vials, draw 150–300 IU into 1–3 mL of saline and infiltrate the entire blanched area and the suspected arterial course (angular artery at the nasolabial fold, extending toward the nasal sidewall). A 30-gauge needle is too fine for adequate dispersion - use a 27-gauge or larger and fan the area.
- Repeat every 60–90 minutes until capillary refill improves and colour returns, escalating to 500 IU or more if there is no response. Higher total doses are acceptable; there is no meaningful maximum in an evolving occlusion.
- Warm compresses to promote vasodilation, topical 2% nitroglycerin paste over the affected area (evidence is weak but harm is low, avoiding the eye), and keep her calm and warm.
- Do not let her leave without a plan. The clinic closing in 50 minutes is irrelevant - arrange a same-evening review or transfer to the emergency department with a handover letter.
- Seek specialist input early: oculoplastic or dermatologic surgery, and ophthalmology if there is any visual change.
2. She asks whether the previously placed filler in the same area will also dissolve, and whether the remaining syringe can be used once she recovers. How do you answer?
Read the worked answer
Yes - and that is acceptable. Hyaluronidase is not selective: it will degrade the 1 mL placed eight months ago as well as today's 0.4 mL. The goal is reperfusion, not preservation of cosmetic result, and tissue loss on the nasal ala would be far worse than losing volume. Explain this before injecting so she is not surprised by a flattened, softer nose in the coming weeks.
On re-injection:
- Discard the remaining product from today's syringe - it is a single-use device and, more importantly, re-injecting into recently compromised, hyaluronidase-saturated tissue is unsafe.
- Do not plan further filler in this region until the tissue is fully healed, typically at least 4–8 weeks, and then only after a frank discussion of the risk.
- If she wants nasal contouring later, consider a cannula-based technique with smaller volumes, one syringe at a time, and avoid high-risk terminal branches.
- Document her allergy history is negative but note that repeated hyaluronidase exposure can rarely provoke hypersensitivity.
3. Design the follow-up and wound care plan, and state what would trigger escalation.
Read the worked answer
Follow-up:
- Review at 12–24 hours, then daily for the first 3–5 days, with photographs at each visit.
- Give her written red-flag instructions and a direct contact number; do not rely on her self-triaging.
Local care: gentle cleansing, petrolatum or a non-adherent dressing, avoid nicotine and caffeine (vasoconstrictors), keep warm, and avoid pressure on the area (no glasses resting on the nasal bridge, no nasal strips).
Escalation triggers:
- Persistent pallor or mottling beyond 24–48 hours, or progression to blistering, dusky necrosis, or eschar.
- Any visual symptom - ophthalmology emergency.
- Signs of infection.
Adjuncts and honesty about them: sildenafil, systemic steroids, and hyperbaric oxygen are reported but unproven; antibiotics are only for established infection, not prophylaxis. Aspirin is sometimes used as an antithrombotic adjunct but has limited evidence.
Documentation: timed note of onset, product, volume, needle size, agent dose, serial photographs, and a same-day incident note. A full-thickness nasal defect is a life-altering injury and litigation risk is high - transparency serves the patient and the record.